Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 4, 2006

Adeza Biomedical Corporation

(Exact name of registrant as specified in its charter)

000-20703
(Commission File Number)

Delaware		77-0054952
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation)

1240 Elko Drive
Sunnyvale, California 94089
(Address of principal executive offices, with zip code)

(408) 745-0975
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

EXHIBIT 99.2

Table of Contents

Item 2.02 Results of Operations and Financial Condition

     On May 4, 2006 Adeza Biomedical Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2006. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 8.01 Other Events

     On May 4, 2006, the Company issued a press release announcing the submission to the United States Food and Drug Administration of a new drug application for Gestiva^TM, its product candidate for the prevention of recurrent preterm birth. The press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

     (c) Exhibits.

		Exhibit 99.1		Press release dated May 4, 2006
		Exhibit 99.2		Press release dated May 4, 2006

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ADEZA BIOMEDICAL CORPORATION
Date: May 4, 2006		By:		/s/          Mark D. Fischer Colbrie
				Mark D. Fischer-Colbrie
				Vice President, Finance and Administration and Chief
				Financial Officer

Table of Contents

EXHIBIT INDEX

Exhibit
number		Description
99.1		Press release dated May 4, 2006
99.2		Press release dated May 4, 2006